| [1] |
Momand J,Zambetti GP,Olson DC, et al. The oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation[J]. Cell, 1992, 69(7): 1237-1245.
|
| [2] |
Michael D,Oren M. The p53-Mdm2 module and the ubiquitin system[J]. Semin Cancer Biol, 2003, 13(1): 49-58.
|
| [3] |
Zhang Z,Zhang R. p53-independent activities of MDM2 and their relevance to cancer therapy[J]. Curr Cancer Drug Targets, 2005, 5(1): 9-20.
|
| [4] |
Bond GL,Hu W,Levine A, et al. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect[J]. Cancer Res, 2005, 65(13): 5481-5484.
|
| [5] |
Bond GL,Hu W,Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans[J]. Cell, 2004, 119(5): 591-602.
|
| [6] |
王倩,谭诗云,吴鹏波,等. MDM2-309 T/G基因多态性与食管癌易感性关系的Meta分析[J].疑难病杂志, 2017, 16(1): 75-79.
|
| [7] |
Marcel V,Palmero EI,Falagan-Lotsch P, et al. TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis[J]. J Med Genet, 2009, 46(11): 766-772.
|
| [8] |
Grochola LF,Zeron-Medina J,Meriaux S, et al. Single-nucleotide polymorphisms in the p53 signaling pathway[J]. Cold Spring Harb Perspect Biol, 2010, 2(5): a001032.
|
| [9] |
Boersma BJ,Howe TM,Goodman JE, et al. Association of breast cancer outcome with status of p53 and MDM2 SNP309[J]. J Natl Cancer Inst, 2006, 98(13): 911-919.
|
| [10] |
Asomaning K,Reid AE,Zhou W, et al. MDM2 promoter polymorphism and pancreatic cancer risk and prognosis[J]. Clin Cancer Res, 2008, 14(12): 4010-4015.
|
| [11] |
Zhuo X,Ye H,Li Q, et al. Is MDM2 SNP309 variation a risk factor for head and neck carcinoma?: an updated meta-analysis based on 11,552 individuals[J]. Medicine(Baltimore), 2016, 95(9): e2948.
|
| [12] |
Yu H,Li H,Zhang J, et al. Influence of MDM2 polymorphisms on squamous cell carcinoma susceptibility: a meta-analysis[J]. Onco Targets Ther, 2016, 9: 6211-6224.
|
| [13] |
Yang XI,Zhu Y,Ye D, et al. Association of MDM2 promoter T309G polymorphism with oral cancer risk: a meta-analysis of 3,536 subjects[J]. Mol Clin Oncol, 2016, 5(1): 175.
|
| [14] |
Xue Z,Zhu X,Teng Y. Relationship between murine double minute 2 (MDM2) T309G polymorphism and endometrial cancer risk: a meta-analysis[J]. Med Sci Monit, 2016, 22: 3186-3190.
|
| [15] |
Xie L,Chen T,Hu H, et al. Association between MDM2 SNP309T>G polymorphism and the risk of bladder cancer: new data in Chinese population and an update meta-analysis[J]. Transl Androl Urol, 2016, 5(S1): AB265.
|
| [16] |
Wo X,Han D,Sun H, et al. MDM2 SNP309 contributes to tumor susceptibility: a meta-analysis[J]. J Genet Genomics, 2011, 38(8): 341-350.
|
| [17] |
Wang LH,Wang X,Xu WT, et al. MDM2 rs2279744 polymorphism and endometrial cancer: a meta-analysis[J]. Tumour Biol, 2014, 35(4): 3167-3170.
|
| [18] |
Wan Y,Wu W,Yin Z, et al. MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis[J]. BMC cancer, 2011, 11: 208.
|
| [19] |
Tian X,Wang B,Guo J, et al. The MDM2 T309G polymorphism and risk of lung cancer: an updated meta-analysis of 10,186 cases and 14,155 controls[J]. Panminerva Med, 2016, 58(4): 341-348.
|
| [20] |
Levav-Cohen Y,Goldberg Z,Tan KH, et al. The p53-Mdm2 loop: a critical juncture of stress response[J]. Subcell Biochem, 2014, 85:161-186.
|
| [21] |
He X,Chen P,Yang K, et al. Association of MDM2 polymorphism with risk and prognosis of leukemia: a meta-analysis[J]. Acta Haematol, 2015, 133(4): 365-371.
|
| [22] |
Gao J,Kang AJ,Lin S, et al. Association between MDM2 rs 2279744 polymorphism and breast cancer susceptibility: a meta-analysis based on 9,788 cases and 11,195 controls[J]. Ther Clin Risk Manag, 2014, 10(1): 269-277.
|
| [23] |
Chen W,Wu Q,Ren H. Meta-analysis of associations between MDM2 SNP309 polymorphism and gastric cancer risk[J]. Biomed Rep, 2014, 2(1): 105-111.
|
| [24] |
Lei C,Zhang W,Fan J, et al. MDM2 T309G polymorphism and esophageal cancer risk: a meta-analysis[J]. Int J Clin Exp Med, 2015, 8(8): 13413-13416.
|
| [25] |
Bilbao-Aldaiturriaga N,Askaiturrieta Z,Granado-Tajada I, et al. A systematic review and meta-analysis of MDM2 polymorphisms in osteosarcoma susceptibility[J]. Pediatr Res, 2016, 80(4):472-479.
|
| [26] |
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol, 2010, 25(9): 603-605.
|
| [27] |
杨军,刘运海. MDM2启动子309位点多态性与胶质母细胞瘤易感性的关系[J].山东医药, 2011, 51(29): 87-88.
|
| [28] |
Zawlik I,Kita D,Vaccarella S, et al. Common polymorphisms in the MDM2 and TP53 genes and the relationship between TP53 mutations and patient outcomes in glioblastomas[J]. Brain Pathol, 2009, 19(2): 188-194.
|
| [29] |
Tsuiki H,Nishi T,Takeshima H, et al. Single nucleotide polymorphism 309 affects murin-double-minute 2 protein expression but not glioma tumorigenesis[J]. Neurol Med Chir (Tokyo), 2007, 47(5): 203- 208.
|
| [30] |
Khatri RG,Navaratne K,Weil RJ. The role of a single nucleotide polymorphism of MDM2 in glioblastoma multiforme[J]. J Neurosurg, 2008, 109(5): 842-848.
|
| [31] |
El Hallani S,Marie Y,Idbaih A, et al. No association of MDM2 SNP309 with risk of glioblastoma and prognosis[J]. J Neurooncol, 2007, 85(3): 241-244.
|
| [32] |
Dimitriadi M,Poulogiannis G,Liu L, et al. p53-independent mechanisms regulate the P2-MDM2 promoter in adult astrocytic tumours[J]. Br J Cancer, 2008, 99(7): 1144-1152.
|
| [33] |
Hunziker A,Jensen MH,Krishna S. Stress-specific response of the p53-Mdm2 feedback loop[J]. BMC Syst Biol, 2010, 4: 94.
|